This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Clinical Trials
Phoenix
Phase 3, Multicenter, Randomized, Double-masked, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in the Treatment of Geographic Atrophy.
Overview
The Phoenix trial is testing a new potential treatment for Geographic Atrophy. Geographic atrophy (GA) is an advanced form of dry age-related macular degeneration (commonly referred to as dry AMD). Dry AMD is a disease that affects part of the back of the eye called the macula. In GA, there are large areas of damaged tissue causing central blind spots, which may affect the fovea (the centre of one’s vision where visual acuity is the highest). This causes difficulty in reading or recognising faces.
The drug being investigated in this trial is called Tinlarebant. It is intended to prevent the accumulation of vitamin A-based toxins (bisretinoids) that contribute to disease progression in GA patients. By reducing the amount of vitamin A delivered to the eye, the study drug aims to reduce the formation of bisretinoids as a means to preserve the health of retinal tissues.
This study will assess the efficacy and safety of tinlarebant for the treatment of GA. As part of the study, suitable participants will be screened to determine their eligibility. If eligible, participants will be randomised to receive either Tinlarebant 5mg in the form of an oral tablet, or placebo tablet. The drug will be administed as an oral tablet, to be taken once a day for up to 24 months.
This study would require participants to attend CERA every 3 months for the 24-month duration of the trial.
For further information about this study please contact the Cerulea on (03) 8638 5300 or email info@ceruleaclinicaltrials.org.au
- Principal Investigator
Professor Robyn Guymer AM
The Phoenix trial is testing a new potential treatment for Geographic Atrophy. Geographic atrophy (GA) is an advanced form of dry age-related macular degeneration (commonly referred to as dry AMD). Dry AMD is a disease that affects part of the back of the eye called the macula. In GA, there are large areas of damaged tissue causing central blind spots, which may affect the fovea (the centre of one’s vision where visual acuity is the highest). This causes difficulty in reading or recognising faces.
The drug being investigated in this trial is called Tinlarebant. It is intended to prevent the accumulation of vitamin A-based toxins (bisretinoids) that contribute to disease progression in GA patients. By reducing the amount of vitamin A delivered to the eye, the study drug aims to reduce the formation of bisretinoids as a means to preserve the health of retinal tissues.
This study will assess the efficacy and safety of tinlarebant for the treatment of GA. As part of the study, suitable participants will be screened to determine their eligibility. If eligible, participants will be randomised to receive either Tinlarebant 5mg in the form of an oral tablet, or placebo tablet. The drug will be administed as an oral tablet, to be taken once a day for up to 24 months.
This study would require participants to attend CERA every 3 months for the 24-month duration of the trial.
For further information about this study please contact the Cerulea on (03) 8638 5300 or email info@ceruleaclinicaltrials.org.au
- Principal Investigator
Learn more
View this study on ClinicalTrials.gov
See the ClinicalTrials.gov database listing for more detailed information about this study.